Understanding SCAND3: A Potential Drug Target and Biomarker (G114821)

Target Name: SCAND3

NCBI ID: G114821

SCAND3

Understanding SCAND3: A Potential Drug Target and Biomarker

SCAND3 (FAM200D) is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and kidney. It is a member of the FAM (family of cytoskeletal proteins) family and is known for its role in cell signaling.

One of the unique features of SCAND3 is its ability to interact with multiple signaling pathways, including the TGF-β pathway, the Wnt pathway, and the Notch pathway. This makes it an attractive drug target for researchers because it has the potential to intervene in a wide range of physiological processes.

SCAND3 has also been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This has led to its potential as a biomarker for these diseases.

One of the key challenges in studying SCAND3 is its highly expressed expression in many different tissues, which can make it difficult to isolate and study the protein in a controlled manner. Additionally, the structure and function of SCAND3 are not well understood, which can make it difficult to design and optimize small molecules for potential drug candidates.

Despite these challenges, research into SCAND3 is ongoing and has the potential to shed light on its role in various diseases. One approach being explored is the use of small molecules to inhibit SCAND3's activity, which could be a potential strategy for targeting the protein in disease.

In addition to its potential as a drug target, SCAND3 also has potential as a biomarker. Its expression has been shown to be elevated in a variety of tissues and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. Additionally, the protein has been shown to play a role in the development and progression of these diseases, which makes it an attractive candidate for use as a biomarker.

Overall, SCAND3 is a protein that is being actively studied as a potential drug target and biomarker. Its unique ability to interact with multiple signaling pathways and its involvement in the development and progression of various diseases make it an intriguing target for research. Further studies are needed to fully understand its role and potential as a drug and biomarker.

Protein Name: SCAN Domain Containing 3

The "SCAND3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCAND3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets